Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 13/20 | 0.51 |
| ▸ | CALCA | P06881 | 3/20 | 0.50 |
| ▸ | ADM2 | Q7Z4H4 | 4/20 | 0.48 |
| ▸ | RAMP1 | O60894 | 6/20 | 0.47 |
| ▸ | CALCB | P10092 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549672 | 0.89 | CALCRL (0.48) | CALCRLCALCARAMP1 | |
| SCHEMBL16658950 | 0.89 | CALCRL (0.48) | CALCRLCALCARAMP1 | |
| SCHEMBL13272817 | 0.86 | CALCA (0.50) | CALCRLCALCAADM2RAMP1CALCB | |
| SCHEMBL13671264 | 0.86 | CALCA (0.50) | CALCRLCALCAADM2RAMP1CALCB | |
| SCHEMBL1700141 | 0.86 | CALCA (0.50) | CALCRLCALCAADM2RAMP1CALCB | |
| SCHEMBL24220794 | 0.86 | CALCA (0.50) | CALCRLCALCAADM2RAMP1CALCB | |
| SCHEMBL260524 | 0.86 | CALCA (0.50) | CALCRLCALCAADM2RAMP1CALCB | |
| SCHEMBL550614 | 0.86 | CALCA (0.50) | CALCRLCALCAADM2RAMP1CALCB | |
| SCHEMBL549390 | 0.86 | CALCA (0.50) | CALCRLCALCAADM2RAMP1CALCB | |
| SCHEMBL13192357 | 0.86 | CALCA (0.50) | CALCRLCALCAADM2RAMP1CALCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | CALCRL 3/4885CALCA 15/4885ADM2 87/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | CALCRL 34/4885CALCA 274/4885ADM2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.